- Home
- ELLO vs KROS Comparison
ELLO vs KROS Comparison
Compare ELLO & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELLO | KROS |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.4M | 206.0M |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ELLO | KROS |
|---|---|---|
| Price | $21.90 | $11.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.86 |
| AVG Volume (30 Days) | 1.8K | ★ 149.4K |
| Earning Date | 03-31-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.00 | $9.69 |
| 52 Week High | $30.34 | $22.55 |
Technical Indicators
Market Signals| Indicator | ELLO | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 55.62 | 53.46 |
| Support Level | $21.72 | $10.59 |
| Resistance Level | $23.13 | $11.69 |
| Average True Range (ATR) | 0.74 | 0.43 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 54.15 | 54.07 |
Price Performance
Historical ComparisonAbout ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions. Geographically, the company operates in segments: Italy; Spain; USA; Netherland and Israel. It derives maximum revenue from Spain.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.